Patents by Inventor Ouathek Ouerfelli

Ouathek Ouerfelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220356163
    Abstract: The present technology relates generally to compounds, compositions, and methods useful for treating, preventing, and/or ameliorating pathogenic cellular proliferation, angiogenesis, cancer, metastatic disease, and/or a pathogenic vascular proliferative disease in a subject.
    Type: Application
    Filed: September 30, 2020
    Publication date: November 10, 2022
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Robert BENEZRA, Ouathek OUERFELLI, Guangli YANG
  • Publication number: 20220257601
    Abstract: Disclosed herein are compounds and methods for the inhibition of the RNF1 or RNF2 subunit of polycomb repressive complex 1 (PRC1) for the treatment of metastatic cancer, such as metastatic castration-resistant prostate cancer. The inhibitors can be combined with checkpoint inhibitors such as PD-1 inhibitors, PD-L 1 inhibitors, or CTLA-4 inhibitors.
    Type: Application
    Filed: June 26, 2020
    Publication date: August 18, 2022
    Applicants: Board of Regents, The University of Texas System, Memorial Sloan Kettering Cancer Center
    Inventors: Filippo Giancotti, Ouathek Ouerfelli, Wenjing Su, Guangli Yang, Howard Scher, Mohammad Marzabadi
  • Patent number: 11413354
    Abstract: The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: August 16, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Ouathek Ouerfelli, Guangbin Yang, Sarah M. Cheal, Steve Larson
  • Publication number: 20210330805
    Abstract: The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 28, 2021
    Inventors: Ouathek OUERFELLI, Guangbin YANG, Sarah M. CHEAL, Steve LARSON
  • Patent number: 11098021
    Abstract: Described herein are phenylsulfonamido-benzofuran derivatives, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, methods, uses, and kits involving compounds of Formulae (I), (II), (III), (IV), (V), or (VI) for treating and/or preventing proliferative diseases (e.g. cancers, inflammatory diseases, and autoimmune diseases) in a subject. The compounds and pharmaceutical compositions as described herein inhibit at least one protein of the BCL-2 family in a biological sample or subject to treat and/or prevent a proliferative disease. In certain embodiments, compounds described herein are selective inhibitors of MCL-1, a BCL-2 family member protein.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: August 24, 2021
    Assignees: Memorial Sloan-Kettering Cancer Center, Albert Einstein College of Medicine, Inc.
    Inventors: Emily H. Cheng, Paul Jeng, Ouathek Ouerfelli, James Hsieh, Guangli Yang, Evripidis Gavathiotis
  • Publication number: 20210188787
    Abstract: Provided herein are DOTA-containing compounds (e.g., compounds of Formula (I)) and complexes that are reactive with an enzyme activator (e.g., a peroxidase) and covalently bind a target analyte (e.g., a protein) in a catalyzed reporter deposition assaying method. The DOTA-containing compounds and complexes are advantageous over existing reporter compounds and complexes because the DOTA moiety allows detection of the reporter moiety by use of mass spectrometry imaging microscopy.
    Type: Application
    Filed: June 13, 2019
    Publication date: June 24, 2021
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Ouathek Ouerfelli, Guangbin Yang, Travis Jason Hollmann
  • Publication number: 20210163441
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: January 26, 2021
    Publication date: June 3, 2021
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Publication number: 20210145988
    Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., 225Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
    Type: Application
    Filed: July 5, 2018
    Publication date: May 20, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Sarah M. CHEAL, Michael MCDEVITT, Ouathek OUERFELLI, Steven M. LARSON, Guangbin YANG
  • Publication number: 20210107987
    Abstract: Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.
    Type: Application
    Filed: February 19, 2019
    Publication date: April 15, 2021
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Isabelle Riviere, Ouathek Ouerfelli, Xiuyan Wang, Frances Weis-Garcia
  • Patent number: 10975051
    Abstract: Described herein are phenylsulfonamido-benzofuran derivatives, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, methods, uses, and kits involving compounds of Formulae (I), (II), (III), (IV), (V), or (VI) for treating and/or preventing proliferative diseases (e.g. cancers, inflammatory diseases, and autoimmune diseases) in a subject. The compounds and pharmaceutical compositions as described herein inhibit at least one protein of the BCL-2 family in a biological sample or subject to treat and/or prevent a proliferative disease. In certain embodiments, compounds described herein are selective inhibitors of MCL-1, a BCL-2 family member protein.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: April 13, 2021
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Emily H. Cheng, Paul Jeng, Ouathek Ouerfelli, James Hsieh, Guangli Yang
  • Patent number: 10934271
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: March 2, 2021
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Publication number: 20200354335
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: July 29, 2020
    Publication date: November 12, 2020
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10766875
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: September 8, 2020
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Publication number: 20200115361
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 16, 2020
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10556882
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 11, 2020
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10526310
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: January 7, 2020
    Assignees: Aragon Pharmaceuticals Inc., Sloan Kettering Institute for Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Publication number: 20190330182
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 31, 2019
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Publication number: 20190241539
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: April 15, 2019
    Publication date: August 8, 2019
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10308630
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 4, 2019
    Assignees: Sloan-Kettering Institute for Cancer Research, Aragon Pharmaceuticals, Inc.
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Publication number: 20180258067
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 13, 2018
    Inventors: Anna DILHAS, Mark R. HERBERT, Ouathek OUERFELLI, Nicholas D. Smith